21 May 2024
21 May 2024 Watkin Jones plc (the ‘Group’) HY Results for the six months ended 31 March 2024 Continued operational progress, positioning for market…
CRANSWICK plc: PRELIMINARY RESULTS A year of strong financial and strategic progress 21 May 2024 Cranswick plc (“Cranswick” or “the Company” or “the Group”),…
Caledonia Investments plc Final results for the year ended 31 March 2024 Financial highlights Year Year 31 March 2024 31 March 2023…
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be…
21 May 2024 Assura plc Good operational and strategic progress; further dividend increase announced Assura plc (“Assura”), the specialist healthcare property investor and developer,…
Issued: 21 May 2024, London UK GSK announces positive results from phase III severe asthma trials of depemokimab · Primary endpoints met in SWIFT-1 and SWIFT-2 trials…
20 May 2024
20 May 2024 AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore Operationally ready by 2029, it will be the…
17 May 2024
LAND SECURITIES GROUP PLC (“Landsec”) Results for the year ended 31 March 2024 Continued operational strength, as values for best assets begin to stabilise…